ClinicalTrials.gg
CompletedNCT00150371CANACTFASTUpdated Feb 18, 2021

Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration

A Phase 3 interventional study of atorvastatin in Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 84 sites in Canada. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Non-randomized
Ages
30 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
9th of 75
1,100 · median 148
Started
2004
with 2 others
Phase 3
31 of 77
none open now
Registered
6th of 77
by date
Lead sponsor
10 of 77
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 9th largest by enrollment of the 75 interventional ones that give a count, is one of 3 that started in 2004, is one of 31 in phase 3, and was the 6th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 30 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

The objective of this study is to assess the effectiveness of an atorvastatin treatment regimen involving starting doses between 10 and 80 mg, followed by a single-step titration (except for subjects started at 80mg), if required

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • (D006937)
04

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30 to 79 years old
  • Triglyceride level 6.8 mmol/L at screening
  • LDL-C of 5.7 mmol/L at screening

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women, or women of not using an acceptable method of . The latter are defined as: abstinence, surgical sterilization, oral contraceptives for at least 3 cycles, intrauterine device, implant, depot injection, or barrier method in conjunction with contraceptive foam or jelly.
  • Subjects whose blood cholesterol levels are controlled (LDL-C targets) with statins other than atorvastatin
  • Subjects receiving statin doses higher than the following: 10-40mg for simvastatin , 20-40mg for fluvastatin, pravastatin and lovastatin and 10-20 mg for rosuvastatin. Subjects already treated with atorvastatin at the time of screening are not eligible unless atorvastatin has been discontinued at least 2 months prior to screening
  • Subjects receiving 2 or more lipid lowering agents are excluded (statins + resins or fibrates or niacin or fish oils)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion (%) of subjects achieving their LDL-C target after 12 weeks of treatment according to their 10-year CHD risk category (based on the new canadian guidelines on the management and treatment of dyslipidemia).

Secondary outcomes

  1. The global proportion (%) of patients reaching targets when risk categories are combined The proportion (%) of subjects achieving BOTH their LDL-C and TC/HDL-C ratio targets after 6 and 12 weeks of treatment, globally and according to their 10-year

07

Study locations

84 sites
  • Pfizer Investigational Site
    Calgary, Alberta T2E 7C5, Canada
  • Pfizer Investigational Site
    Calgary, Alberta T3E 0C5, Canada
  • Pfizer Investigational Site
    Calgary, Alberta T3G 3J9, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5K 2A2, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5N 2N8, Canada
  • Pfizer Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • Pfizer Investigational Site
    Coquitlam, British Columbia V3K 3V9, Canada
  • Pfizer Investigational Site
    Kelowna, British Columbia V1Y 2H4, Canada
  • Pfizer Investigational Site
    Langley, British Columbia V3A 4H9, Canada
  • Pfizer Investigational Site
    Surrey, British Columbia V3R 3P1, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 3J5, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8T 3P2, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R2V 3P4, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • Pfizer Investigational Site
    Moncton, New Brunswick E1G 1A7, Canada
  • Pfizer Investigational Site
    Rothesay, New Brunswick E2E 2R2, Canada
  • Pfizer Investigational Site
    Saint John, New Brunswick E2K 2T8, Canada
  • Pfizer Investigational Site
    Halifax, B3K 5R3, Nova Scotia, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 1Y6, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3K 5R3, Canada
  • Pfizer Investigational Site
    Brampton, Ontario L6T 3J1, Canada
  • Pfizer Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Pfizer Investigational Site
    Courtice, Ontario L1E 3C3, Canada
  • Pfizer Investigational Site
    Downsview, Ontario M3M 3E5, Canada
  • Pfizer Investigational Site
    Fort Erie, Ontario L2A1Z3, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • Pfizer Investigational Site
    Hawkesbury, Ontario K6A 1A1, Canada
  • Pfizer Investigational Site
    Kitchener, Ontario N2C 2N9, Canada
  • Pfizer Investigational Site
    Lindsay, Ontario K9V 6C5, Canada
  • Pfizer Investigational Site
    Markham, Ontario L6B 1A1, Canada
  • Pfizer Investigational Site
    Midland, Ontario L4R 4P4, Canada
  • Pfizer Investigational Site
    Napanee, Ontario K7R 2G3, Canada
  • Pfizer Investigational Site
    Newmarket, Ontario L3Y 5G8, Canada
  • Pfizer Investigational Site
    Niagara Falls, Ontario L2E 7H1, Canada
  • Pfizer Investigational Site
    North Bay, Ontario P1B 2H3, Canada
  • Pfizer Investigational Site
    North York, Ontario M3J 1N2, Canada
  • Pfizer Investigational Site
    Oshawa, Ontario L1H 1B9, Canada
  • Pfizer Investigational Site
    Oshawa, Ontario L1J 2K9, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1C 1S6, Canada
  • Pfizer Investigational Site
    Saint Catherines, Ontario L2N 7H8, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    St. Catherines, Ontario L2S 3V7, Canada
  • Pfizer Investigational Site
    Thornhill, Ontario L3T 4X1, Canada
  • Pfizer Investigational Site
    Thunder Bay, Ontario P7E 4Z3, Canada
  • Pfizer Investigational Site
    Thunder Bay, Ontario P7E 6E7, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M8V 3X8, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • Pfizer Investigational Site
    Windsor, Ontario N8X 1K4, Canada
  • Pfizer Investigational Site
    Charlottetown, Prince Edward Island C1A 1L2, Canada
  • Pfizer Investigational Site
    Montague, Prince Edward Island C0A 1R0, Canada
  • Pfizer Investigational Site
    Amos, Quebec J9T 1T8, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Pfizer Investigational Site
    Cowansville, Quebec J2K 2X9, Canada
  • Pfizer Investigational Site
    Greenfield Park, Quebec J4V 2G8, Canada
  • Pfizer Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Pfizer Investigational Site
    Greenfield Park, Quebec J4V2H1, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7N 2k2, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7V 2W3, Canada
  • Pfizer Investigational Site
    Le Gardeur, Quebec J5Z 3C4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3A 1A1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3S 2W1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H4N 2W2, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H4V 2R8, Canada
  • Pfizer Investigational Site
    Plessisville, Quebec G6L 3J1, Canada
  • Pfizer Investigational Site
    Saint-Eustache, Quebec J7P 2V1, Canada
  • Pfizer Investigational Site
    Salaberry Du Valleyfield, Quebec J6S 4Z5, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 4J6, Canada
  • Pfizer Investigational Site
    St. Leonard, Quebec H1S 3A9, Canada
  • Pfizer Investigational Site
    Ste. Foy, Quebec G1V 4G2, Canada
  • Pfizer Investigational Site
    Vaudreuil, Quebec J7V 8P9, Canada
  • Pfizer Investigational Site
    Regina, Saskatchewan S4P 3X1, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7H 0W6, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 1N8, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 7H9, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7L 2W1, Canada
  • Pfizer Investigational Site
    Quebec, G1S 2L6, Canada
  • Pfizer Investigational Site
    St. John's, A1E 2C2, Canada
  • Pfizer Investigational Site
    St. John's, A1E 2E2, Canada
08

References and documents

Publications

  • Ur E, Langer A, Rabkin SW, Calciu CD, Leiter LA; CanACTFAST Study Investigators. Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. Can J Cardiol. 2010 Feb;26(2):80-6. doi: 10.1016/s0828-282x(10)70003-9. PubMed 20151053 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Jun 2004
CompletionActual
May 2005
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00150371
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Jun 2004
Completion
May 2005
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion